EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.

by Sara Charmsaz, Kirrilee Beckett, Fiona M Smith, Claudia Bruedigam, Andrew S Moore, Fares Al-Ejeh, Steven W Lane, Andrew W Boyd
Published 2015-01-01

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist

by Cassandra L. Pegg, Leanne T. Cooper, Jing Zhao, Michael Gerometta, Fiona M. Smith, Michael Yeh, Perry F. Bartlett, Jeffrey J. Gorman, Andrew W. Boyd
Published 2017-07-01

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma

by Carolin Offenhäuser, Fares Al-Ejeh, Simon Puttick, Kathleen S. Ensbey, Zara C. Bruce, Paul R. Jamieson, Fiona M. Smith, Brett W. Stringer, Benjamin Carrington, Adrian V. Fuchs, Craig A. Bell, Rosalind Jeffree, Stephen Rose, Kristofer J. Thurecht, Andrew W. Boyd, Bryan W. Day
Published 2018-12-01

Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome

by Mengnan Li, Shin-ya Nishio, Chie Naruse, Meghan Riddell, Sabrina Sapski, Tatsuya Katsuno, Takao Hikita, Fatemeh Mizapourshafiyi, Fiona M. Smith, Leanne T. Cooper, Min Goo Lee, Masahide Asano, Thomas Boettger, Marcus Krueger, Astrid Wietelmann, Johannes Graumann, Bryan W. Day, Andrew W. Boyd, Stefan Offermanns, Shin-ichiro Kitajiri, Shin-ichi Usami, Masanori Nakayama
Published 2020-03-01